Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
advanced breast cancer; chemotherapy; endocrine/hormone therapy; Europe; guideline
Abstract :
[en] Abstract Background: International guidelines for hormone-receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (BC) recommend sequential lines of hormonal therapy (HT), and only recommend chemotherapy for patients with extensive visceral involvement or rapidly progressive disease. This study evaluated actual physician-reported treatments for advanced BC in Europe. Methods: We conducted a retrospective chart review of 355 postmenopausal women with HR+, HER2- advanced BC who progressed on >/=1 line of HT (adjuvant or advanced) and completed >/=1 line of chemotherapy (advanced). Treatment choice was evaluated for each line of therapy. Results: Of 355 patients, 111 (31%) received first-line chemotherapy, whereas 218 (61%) and 26 (7%) switched from HT to chemotherapy in second and third line, respectively. More patients receiving first-line HT had bone metastases (73% vs 27% chemotherapy). Patients treated with first-line chemotherapy had more brain (12% vs 3% HT) or extensive liver (13% vs 6% HT) metastases. Subgroup analysis of 188 patients who received first-line HT and had de novo advanced BC or relapsed/recurrent disease more than 1 year after adjuvant therapy found that the majority (89%; n = 167) of these patients switched to chemotherapy in second line. However, among these 167 patients, 27% had no significant changes in metastases between first and second line. Among the 73% of patients who had significant changes in metastases, 20% had no brain metastases or extensive visceral disease. Conclusions: Our study suggests that the guideline-recommended use of multiple HT lines is open to interpretation and that optimal treatment for European postmenopausal women with HR+, HER2- advanced BC who responded to HT may not be achieved.
Disciplines :
Oncology
Author, co-author :
Andre, Fabrice
Neven, Patrick
Marinsek, Nina
Zhang, Jie
Baladi, Jean-Francois
Degun, Ravi
Benelli, Giancarlo
Saletan, Stephen
Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Language :
English
Title :
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 1.2013. Available at: www.nccn.com [Last accessed 4 December 2013]
Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52
Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007;25:191-5
DeKoven M, Bonthapally V, Jiao X, et al. Treatment pattern by hormone receptors and HER2 status in patients with metastatic breast cancer in the UK, Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp Eff Res 2012;1:453-63
Jackisch C, Untch M, Chatsiproios D, et al. Adherence to treatment guidelines in breast cancer care-A retrospective analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'. Breast Care (Basel) 2008;3:87-92
Wu XC, Lund MJ, Kimmick GG, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 2012;30:142-50
Wockel A, Varga D, Atassi Z, et al. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study. Onkologie 2010;33:21-8
Wolters R, Wockel A, Wischnewsky M, et al. [Effects of guideline-compliant therapy on the survival of patients with primary breast cancer: results of a retrospective cohort study]. Z Evid Fortbild Qual Gesundhwes 2011;105:468-75
Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010;28:1958-62
Jerusalem G, Marinsek N, Ricci J-F, et al. Clinical management and resource utilisation for hormone-receptor-positive HER2-negative (HR+ HER2~) advanced breast cancer (BC) in Europe. Abstract 336P. Poster presented at: 2012 ESMO Congress, 28 September-2 October 2012, Vienna, Austria
Saad ED. Endpoints in advanced breast cancer: methodological aspects & clinical implications. Indian J Med Res 2011;134:413-18
Verma S, McLeod D, Batist G, et al. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011;16:25-35
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-9
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009;117:69-75
Bouaud J, Messai N, Laouenan C, et al. Elicitating patient patterns of physician non-compliance with breast cancer guidelines using formal concept analysis. Stud Health Technol Inform 2012;180:477-81
Seroussi B, SouletA, Messai N, etal. Patient clinical profiles associated with physician non-compliance despite the use of a guideline-based decision support system: a case study with OncoDoc2 using data mining techniques. AMIA Annu Symp Proc 2012;2012:828-37
Fleeman N, BagustA, Boland A, etal. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess 2011;15:1-93, iii-iv